The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James <https://cancer.osu.edu>) is dedicated to creating a cancer-free world by integrating scientific research with excellence in education and patient-centered care – a strategy that leads to better methods of prevention, detection and treatment.
Ohio State has been designated a National Cancer Institute (NCI) Comprehensive Cancer Center for nearly 50 years and is one of only a few centers funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs provided by the NCI. In its last three formal reviews for five-year redesignation, the university’s cancer program, embodied in the OSUCCC – James, has received the NCI’s highest descriptor of “exceptional”.
The OSUCCC – James has more than $125 million in active cancer-relevant research funding, and $70.4 million of that total – more than half – comes from the NCI. In 2023 alone, Ohio State cancer researchers received 27 new research grants totaling $15.8 million from the NCI.
The OSUCCC – James has nearly 340 full or introductory cancer researchers who collectively represent 12 of the 15 colleges at Ohio State. Each researcher is a member of one of five multidisciplinary research programs: Cancer Control, Leukemia Research, Cancer Biology, Molecular Carcinogenesis and Chemoprevention, or Translational Therapeutics. In 2022, these researchers authored or co-authored 825 publications in peer-reviewed journals, including 174 in journals with impact factors of 10 or higher. Also, 98% of all articles published were collaborative, and over 96% were multi-institutional. In addition, OSUCCC – James researchers lead or assist with nearly 700 clinical trials offering the latest cancer treatments, some of which are available nowhere else. Some 530 of these trials are interventional in focus.
Collaboration and integration
As the cancer program’s 356-bed adult patient-care component, The James is the third-largest cancer hospital in the United States and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical care. Because early diagnosis is the key to successful cancer treatment, The James Cancer Diagnostic Center at the OSUCCC – James provides patients who may have cancer with direct, expedited access to diagnostic testing in a center that is open for same-day or next-day appointments.
The OSUCCC – James since 2014 has enrolled nearly 70,000 patients in a Total Cancer Care® (TCC) protocol for voluntarily sharing deidentified clinical data that advances cancer research and personalizes cancer care. The TCC protocol has been adopted by all 18 member institutions across the United States that constitute the Oncology Research Information Exchange Network (ORIEN), a research collaboration co-founded and co-anchored by the OSUCCC – James and Moffit Cancer Center in Tampa, Florida. Through ORIEN, TCC-consented patients across the nation donate clinical data for research that helps scientists better understand cancer at the molecular level.
Outstanding international reputation
Because of its international reputation for providing outstanding research-based cancer care, the OSUCCC – James is regarded as a global destination of choice, serving patients from all 50 U.S. states, three U.S territories and 85 other countries.
The institution’s Destination Medicine Global Health Care team <https://cancer.osu.edu/destinationmedicine> is dedicated to ensuring that distance and language are no obstacles to receiving the internationally recognized cancer care available at Ohio State.
